Home / Market News / $REGN
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Bank of America Adds Regeneron to 'Value 10' Portfolio

Nov 4, 2026, 7:02 PM UTC · Primary ticker $REGN

Bank of America Securities has added Regeneron Pharmaceuticals to its 'Value 10' portfolio, an equal-weighted quantitative model of S&P 500 stocks with BofA Buy ratings and low trailing P/E multiples. This inclusion is part of a monthly rebalancing process, indicating BofA's quantitative model identifies Regeneron as a value opportunity.

Bank of America Securities has included Regeneron Pharmaceuticals in its 'Value 10' portfolio for November 2026. This is significant for Regeneron as it signals a quantitative endorsement from a major financial institution, potentially increasing investor interest and demand for the stock. The 'Value 10' strategy focuses on S&P 500 stocks with BofA Buy ratings and low trailing P/E multiples, suggesting BofA sees REGN as undervalued with strong fundamentals. For traders, this could lead to short-term positive momentum for REGN, while long-term investors might view it as a confirmation of value. The key opportunity lies in potential increased institutional buying following this public endorsement.

$REGN positive Added to BofA 'Value 10' portfolio
$BAC neutral Firm managing portfolio
$SPX neutral Constituent of S&P 500, from which stocks are selected
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.